Cite
HARVARD Citation
Naqvi, K. et al. (2020). Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 126 (1), pp. 67-75. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Naqvi, K. et al. (2020). Long‐term follow‐up of lower dose dasatinib (50 mg daily) as frontline therapy in newly diagnosed chronic‐phase chronic myeloid leukemia. Cancer. 126 (1), pp. 67-75. [Online].